NCT04675710 2026-02-19
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
31 trialsNCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04759911 2025-11-13
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06374602 2025-09-05
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT04238624 2025-07-02
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04552769 2025-06-05
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT06235216 2024-11-01
SETHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Recruiting
NCT03565536 2024-04-19
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
Phase 2 Completed
NCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT06079333 2023-10-12
NEO-ATACT
Leiden University Medical Center
Phase 2 Recruiting
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT02688608 2022-02-10
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT04574817 2020-10-05
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT02726503 2020-06-17
HOPE
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT03211117 2020-03-25
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Mayo Clinic
Phase 2 Completed
NCT00625846 2020-02-26
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02657369 2019-10-15
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
Phase 2 Terminated
NCT02289144 2019-07-30
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT03002623 2018-12-21
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT01164176 2014-12-02
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Phase 2 Completed
NCT00115739 2014-04-21
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00095693 2014-01-16
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01118065 2013-08-12
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004089 2013-07-10
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019331 2013-06-20
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00786552 2011-01-20
Panthera
University Hospital Schleswig-Holstein
Phase 2 Unknown
NCT00060242 2010-06-11
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 2 Completed